Abstract
Objective This study aimed to investigate the impact of Xuebijing injection on postoperative inflammatory response and liver function in patients who underwent liver resection for hepatocellular carcinoma, and to evaluate its safety and clinical value. Methods The clinical data of 426 HCC patients who underwent partial hepatectomy at the Nanfang Hospital, Southern Medical University from January 2015 to June 2017 were retrospectively studied. These patients were divided into the treatment group and the control group based on whether they were treated with Xuebijing injection or not. After propensity score matching, each group included 101 patients. The preoperative and postoperative WBC, NE%, C-reactive protein (CRP), body temperature, ALT, AST and TBil levels, as well as the occurrence of adverse drug reactions and the days and costs of hospitalization were compared between the two groups. Results There were no significant differences in ALT, AST, TBil, WBC, NE% before surgery between the two groups (P>0.05). When compared with the control group, the WBC, NE%, and CRP in the treatment group were significantly lower than those in the control group on day 3 and 5 after surgery: (11.5±3.2)×109/L vs (10.2±4.0)×109/L, (8.1±2.4)×109/L vs (7.3±2.8)×109/L; ( 78.3±11.6)% vs (73.3±6.4)%, (69.3±12.1)% vs (64.7±7.7)%; (81.2±51.8) mg/L vs (64.2±43.7) mg/L, (51.9±26.3) mg/L vs (44.4±24.0) mg/L, respectively. The differences were significantly difference (P 0.05). The total incidence of adverse drug reactions, postoperative hospital stay and hospitalization costs were not significantly different between the two groups (all P>0.05). Conclusion Xuebijing injection showed a good anti-inflammatory effect with no obvious liver toxicity in patients who underwent liver resection. It demonstrated good safety and could be applied to prevent and treat patients with excessive inflammatory reaction after liver resection. Key words: Xuebijing injection; Hepatectomy; Inflammatory response; Liver function
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
